Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone

NCT00033293 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00033293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00033293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2004
Completion date
December 31, 2022
Enrollment
53 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

localized resectable neuroblastoma, localized unresectable neuroblastoma, regional neuroblastoma, stage 4 neuroblastoma, stage 4s neuroblastoma